Search Within

Steven Maron

  1. "MSK Grad Students"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (8)
Groups
  1. Department of Medicine (17)
  2. Gastrointestinal Oncology Service (17)
  3. MSK Grad Students (17)
  4. Solid Tumor Oncology Division (17)
  5. Computational Oncology Service (16)
  6. Epidemiology and Biostatistics (16)

More Groups

People
  1. Nikolaus Schultz (15)
  2. Walid Chatila (15)
  3. Yelena Janjigian (15)
  4. Geoffrey Ku (12)
  5. Henry Walch (11)
  6. David Ilson (10)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (6)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (3)
Publications
  1. Journal of Clinical Oncology (8)
  2. Clinical Cancer Research (3)
  3. Annals of Surgery (1)
  4. Annals of Surgical Oncology (1)
  5. JCO Precision Oncology (1)
  6. JNCI: Journal of the National Cancer Institute (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (3)
  3. Elsevier Science, Inc. (1)
  4. Lippincott Williams & Wilkins (1)
  5. Nature Publishing Group (1)
  6. Oxford University Press (1)

More Publishers

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Distinct differences in genomic profile of gastric and gastroesophageal junction adenocarcinoma
    Meeting Abstract

    Nakauchi, M.; Walch, H. S.; Chatila, W. K.; Tran, T.; Vos, E. L.; Sihag, S.; Tang, L. H.; Coit, D. G.; Stadler, Z. K.; Janjigian, Y. Y.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Defining and targeting esophagogastric cancer genomic subsets with patient-derived xenografts
    Journal Article

    Moy, R. H.; Walch, H. S.; Mattar, M.; Chatila, W. K.; Molena, D.; Strong, V. E.; Tang, L. H.; Maron, S. B.; Coit, D. G.; Jones, D. R.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Next-generation sequencing of 487 esophageal adenocarcinomas reveals independently prognostic genomic driver alterations and pathways
    Journal Article

    Sihag, S.; Nussenzweig, S. C.; Walch, H. S.; Hsu, M.; Tan, K. S.; Sanchez-Vega, F.; Chatila, W. K.; De La Torre, S. A.; Patel, A.; Janjigian, Y. Y.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria
    Meeting Abstract

    Maron, S. B.; Vanderbilt, C.; Sabwa, S.; Bowman, A.; Chatila, W. K.; Tang, L. H.; Strong, V. E.; Molena, D.; Jones, D. R.; Coit, D. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save